// App-Quantinova.ai

376 : A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors

Researchers

Presenter

  • Shubham Pant

Principal Investigators

  • Pavlos Msaouel

  • Matthew Campbell

  • Shi-Ming Tu

  • Jianjun Gao

  • George Blumenschein

  • Frank Mott

  • Xiuning Le

  • Mehmet Altan

  • Funda Meric-Bernstam

  • Timothy Yap

  • Vivek Subbiah

  • Jordi Rodon

  • Axel Glasmacher

  • Imke Mulder

  • Michael Chisamore

  • Alexander Stevenson

  • Nizar Tannir

Medical Centers

  • D pharma plc, Leeds, UK

  • Merck and Co., Inc., Wheaton, Illinois, USA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Bladder Cancer

  • Non Small Cell Lung cancer

  • Metastatic Renal Cell Cancer

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Tissue polypeptide-specific antigen

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved